| Project/Area Number |
18K10768
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 59010:Rehabilitation science-related
|
|---|
| Research Institution | Hyogo Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
道免 和久 兵庫医科大学, 医学部, 教授 (50207685)
内山 侑紀 兵庫医科大学, 医学部, 講師 (50725992)
|
|---|
| Project Period (FY) |
2018-04-01 – 2022-03-31
|
| Project Status |
Completed (Fiscal Year 2021)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2021: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2020: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2019: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 小児上肢麻痺 / 上肢集中訓練 / 実行可能性 / 安全性 / CI療法 / 脳性麻痺 / 小児 / リハビリテーション |
|---|
| Outline of Final Research Achievements |
Constraint induced movement therapy (CIMT) was performed on six subjects in this study. Four patients showed improvement in Fugl-Meyer Assessment after CIMT. Five patients showed improvement in Jobsen-Taylor Hand Function Test and Pediatric Motor Activity Log-Revised. Follow-up surveys confirmed that the patients generally maintained improvement in upper extremity function 6 months and 1 year after the end of CI therapy.
Safety was confirmed with no adverse events during the intervention in all subjects. Regarding feasibility, five subjects achieved more than 30 hours of training, but in one subject, total training hours were less than 30 hours due to inadequate management.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究の結果から、本邦においてもConstraint induced movement therapy (CI療法) を20歳未満の対象者に実施することで、上肢機能の改善が促されること、その効果が6ヶ月から1年後まで長期的に持続することが示唆された。また、欧米とは違い療法室を中心に実施しなくてはならない本邦の環境においても、CI療法の実施が可能であった。本邦では小児例に対するCI療法の報告はほとんどなく、本研究の結果は、本邦の医療保険制度下においても、患者家族がCI療法を治療手段の１つとして選択できる可能性を示唆するものであると考える。
|
